Newsletter | September 16, 2026

09.16.26 -- Picking Biotech Winners Beyond The Hype With Olivier Litzka

SPONSOR

 

ISPOR Europe 2026

In an era defined by rapid scientific advancement, fiscal pressures, evolving regulations, and growing expectations for equity and transparency, health economics and outcomes research (HEOR) provides the frameworks and insights needed to guide responsible and sustainable healthcare decision making. Thousands of global healthcare stakeholders will convene at ISPOR Europe 2026 to underscore the transformative role of HEOR in guiding better healthcare decisions.

FEATURED ARTICLE

Picking Biotech Winners Beyond The Hype With Olivier Litzka

On this week's episode of the Business of Biotech, Olivier Litzka, Partner at Andera Partners, talks about what it really takes for biotech companies to attract capital, stay focused, and survive the moments when biology and execution punch back.

 

INDUSTRY INSIGHTS

 

Redefining eSource: A Smarter Approach To Clinical Trial Data Capture

Discover how AI-powered extraction and site-centric workflows improve data quality and reduce administrative burdens for research teams.

 

Patient Centric Clinical Trials: Why Transportation Is A Timeline Risk

Address transportation barriers to reduce protocol deviations and data gaps. Strategies that lower travel burden protect study timelines and improve visit adherence for better trial outcomes.

 

Rethinking Trial Access Through Trust-Driven Design And Local Collaboration

Locally embedded research models help sponsors reach underserved populations while reducing burden on patients and health systems alike.

 

GLP-1 Peptides Around The World

Explore how evolving regulations, supply constraints, and reimbursement models shape GLP-1 drug development across the U.S., Europe, and Asia.

 

The Bioprocessing Industry Has A Digital Execution Problem

Digital execution remains a major barrier in manufacturing. Learn how fragmented data, manual decisions, and inconsistent adoption affect the ability to bring complex therapies to patients faster.

 

High Purity Alcohols In Biopharma: Insights In Navigating Compliance

Learn how to mitigate supply chain risks for industrial alcohols and ensure workplace safety through rigorous tracking and reporting protocols.

 

Curia Capabilities Update May 2026: HPAPI & API Development

What is critical when choosing a CDMO as a partner for HPAPI development and manufacturing? Curia's Brian Haney breaks down the key questions, controls, and expertise every innovator should evaluate.
Connect With Life Science Leader: